Company news

Zevra Therapeutics, Inc. news in 2026

Zevra Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Zevra Reports Third Quarter 2026 Financial Results and Corporate Update

November 3, 2026

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

October 20, 2026

Zevra Therapeutics to Present at Upcoming Investor Conferences

September 2, 2026

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

August 25, 2026

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

August 5, 2026

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

August 4, 2026

Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

August 3, 2026

Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

July 24, 2026

Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call

July 22, 2026

Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)

June 23, 2026

Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

June 11, 2026

Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

June 8, 2026

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

May 12, 2026

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

May 6, 2026

Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call

April 21, 2026

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer under Nasdaq Listing Rule 5635(4)

March 23, 2026

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

March 19, 2026

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

March 15, 2026

Zevra Reports Fourth Quarter and Full Year 2025 Financial Results

March 8, 2026

Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer

March 4, 2026

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

March 2, 2026

Zevra Therapeutics to Present at the Citizens Life Sciences Conference

February 25, 2026

Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

February 4, 2026

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

February 2, 2026

Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

January 26, 2026

Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference

January 8, 2026

Calls in 2026

Decks in 2026